Advertisement

Hematologic Cancer Survivorship Management: Lymphoma

  • Maria Alma Rodriguez
  • Leslie Ballas
  • Kristin Simar
Chapter
Part of the MD Anderson Cancer Care Series book series (MDCCS)

Abstract

Lymphoid malignancies are a family of diverse cancers arising in the cells of the immune system. Lymphoid leukemia, lymphoma, and myeloma belong to this category of cancers. This chapter will focus on lymphomas and the late effects of treatment. Lymphomas are broadly categorized into Hodgkin lymphomas, which are uncommon, and non-Hodgkin lymphomas, which are the sixth most common malignancy in men and women. Incidence of non-Hodgkin lymphoma appears to be rising, although the reasons for this are unclear. Treatment for lymphoma has improved substantially over the past 50 years, resulting in a large population of long-term lymphoma survivors. Patients with lymphoma are treated principally with chemotherapy, immunotherapy, radiation, or stem cell transplantation. Surgery generally does not have a role in the treatment of these disorders except in rare cases. Different treatment modalities have different late side effects. In this chapter, we will summarize the most commonly known potential late effects of chemotherapeutic agents and radiation, the few situations in which surgery is used and its long-term effects, and recommended practice for surveillance of recurrence and late effects.

Keywords

Hodgkin Lymphoma Time High Risk Survivorship Care Plan Advanced Practice Nurse Splenic Marginal Zone Lymphoma 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Supplementary material

Suggested Readings

  1. Abrahamsen AF, Andersen A, Nome O, et al. Long-term risk of second malignancy after treatment of Hodgkin’s disease: the influence of treatment, age and follow-up time. Ann Oncol 2002;13:1786–1791.CrossRefGoogle Scholar
  2. Aleman BM, van den Belt-Dusebout AW, De Bruin ML, et al. Late cardiotoxicity after treatment for Hodgkin lymphoma. Blood 2007;109:1878–1886.PubMedCrossRefGoogle Scholar
  3. Alm El-Din MA, El-Badawy SA, Taghian AG. Breast cancer after treatment of Hodgkin’s lymphoma: general review. Int J Radiat Oncol Biol Phys 2008;72:1291–1297.PubMedCrossRefGoogle Scholar
  4. Arden-Close E, Eiser C, Pacey A. Sexual functioning in male survivors of lymphoma: a systematic review. J Sex Med 2011;8:1833–1840.PubMedCrossRefGoogle Scholar
  5. Bhatia S, Ramsay NK, Bantle JP, Mertens A, Robison LL. Thyroid abnormalities after therapy for Hodgkin’s disease in childhood. J Nucl Med 1989;30:255–257.Google Scholar
  6. Centers for Disease Control and Prevention. Advisory committee on immunization practices vaccine recommendations, 2012. http://www.immunize.org/acip/. Updated October 12, 2012. Accessed November 19, 2012.
  7. Chen AB, Punglia RS, Kuntz KM, Mauch PM, Ng AK. Cost effectiveness and screening interval of lipid screening in Hodgkin’s lymphoma survivors. J Clin Oncol 2009;27:5383–5389.PubMedCrossRefPubMedCentralGoogle Scholar
  8. Constine LS, Donaldson SS, McDougall IR, et al. Thyroid dysfunction after radiotherapy in children with Hodgkin’s disease. Cancer 1984;53:878–883.PubMedCrossRefGoogle Scholar
  9. Das P, Ng AK, Earle CC, Mauch PM, Kuntz KM. Computed tomography screening for lung cancer in Hodgkin’s lymphoma survivors: decision analysis and cost-effectiveness analysis. Ann Oncol 2006;17:785–793.PubMedCrossRefGoogle Scholar
  10. De Bruin ML, Burgers JA, Baas P, et al. Malignant mesothelioma after radiation treatment for Hodgkin lymphoma. Blood 2009;113:3679–81.PubMedCrossRefGoogle Scholar
  11. Diller L, Medeiros Nancarrow C, Shaffer K, et al. Breast cancer screening in women previously treated for Hodgkin’s disease: a prospective cohort study. J Clin Oncol 2002;20:2085–2091.PubMedCrossRefGoogle Scholar
  12. Franklin J, Pluetschow A, Paus M, et al. Second malignancy risk associated with treatment of Hodgkin’s lymphoma: meta-analysis of the randomised trials. Ann Oncol 2006;17:1749–1760.PubMedCrossRefGoogle Scholar
  13. Galper SL, Yu JB, Mauch PM, et al. Clinically significant cardiac disease in patients with Hodgkin lymphoma treated with mediastinal irradiation. Blood 2011;117:412–418.PubMedCrossRefGoogle Scholar
  14. Hancock SL, Cox RS, McDougall IR. Thyroid diseases after treatment of Hodgkin’s disease. N Engl J Med 1991;325:599–605.PubMedCrossRefGoogle Scholar
  15. Hancock SL, Tucker MA, Hoppe RT. Factors affecting late mortality from heart-disease after treatment of Hodgkins-disease. JAMA 1993;270:1949–1955.PubMedCrossRefGoogle Scholar
  16. Heidenreich PA, Schnittger I, Strauss HW, et al. Screening for coronary artery disease after mediastinal irradiation for Hodgkin’s disease. J Clin Oncol 2007;25:43–49.PubMedCrossRefGoogle Scholar
  17. Howlader N, Noone AM, Krapcho M, et al. SEER cancer statistics review, 1975–2009 (vintage 2009 populations). Bethesda, MD: National Cancer Institute. http://seer.cancer.gov.csr/1975_2009_pops09/. Published April 2012. Accessed November 21, 2012.
  18. Hull MC, Morris CG, Pepine CJ, Mendenhall NP. Valvular dysfunction and carotid, subclavian, and coronary artery disease in survivors of Hodgkin lymphoma treated with radiation therapy. JAMA 2003;290:2831–2837.PubMedCrossRefGoogle Scholar
  19. Larsen RL, Jakacki RI, Vetter VL, Meadows AT, Silber JH, Barber G. Electrocardiographic changes and arrhythmias after cancer therapy in children and young adults. Am J Cardiol 1992;70:73–77.PubMedCrossRefGoogle Scholar
  20. Mauch PM, Kalish LA, Marcus KC, et al. Long-term survival in Hodgkin’s disease relative impact of mortality, second tumors, infection, and cardiovascular disease. Cancer J Sci Am 1995;1:33–42.PubMedGoogle Scholar
  21. Myrehaug S, Pintilie M, Tsang R, et al. Cardiac morbidity following modern treatment for Hodgkin lymphoma: supra-additive cardiotoxicity of doxorubicin and radiation therapy. Leuk Lymphoma 2008;49:1486–1493.PubMedCrossRefGoogle Scholar
  22. Ng AK, LaCasce A, Travis LB. Long-term complications of lymphoma and its treatment. J Clin Oncol 2011;29:1885–1892.PubMedCrossRefGoogle Scholar
  23. Ogilvy-Stuart AL, Shalet SM. Effect of radiation on the human reproductive system. Environ Health Perspect 1993;101(Suppl 2):109–116.PubMedCrossRefPubMedCentralGoogle Scholar
  24. Orzan F, Brusca A, Gaita F, Giustetto C, Figliomeni MC, Libero L. Associated cardiac lesions in patients with radiation-induced complete heart block. Int J Cardiol 1993;39:151–156.PubMedCrossRefGoogle Scholar
  25. Rodrigues NA, Killion L, Hickey G, et al. A prospective study of salivary gland function in lymphoma patients receiving head and neck irradiation. Int J Radiat Oncol Biol Phys 2009;75:1079–1083.PubMedCrossRefGoogle Scholar
  26. Ron E, Lubin JH, Shore RE, et al. Thyroid cancer after exposure to external radiation: a pooled analysis of seven studies. Radiat Res 1995;141:259–277.PubMedCrossRefGoogle Scholar
  27. Saslow D, Boetes C, Burke W, et al. American cancer society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin 2007;57:75–89.PubMedCrossRefGoogle Scholar
  28. Sklar C, Whitton J, Mertens A, et al. Abnormalities of the thyroid in survivors of Hodgkin’s disease: data from the childhood cancer survivor study. J Clin Endocrinol 2000;85:3227–3232.Google Scholar
  29. Sung JS, Malak SF, Bajaj P, Alis R, Dershaw DD, Morris EA. Screening breast MR imaging in women with a history of lobular carcinoma in situ. Radiology 2011;261:414–420.PubMedCrossRefGoogle Scholar
  30. Swerdlow AJ, Higgins CD, Smith P, et al. Myocardial infarction mortality risk after treatment for Hodgkin disease: a collaborative British cohort study. J Natl Cancer Inst 2007;99:206–214.PubMedCrossRefGoogle Scholar
  31. Travis LB, Gospodarowicz M, Curtis RE, et al. Lung cancer following chemotherapy and radiotherapy for Hodgkin’s disease. J Natl Cancer Inst 2002;94:182–192.PubMedCrossRefGoogle Scholar
  32. Tucker MA, D’Angio GJ, Boice JD Jr, et al. Bone sarcomas linked to radiotherapy and chemotherapy in children. N Engl J Med 1987;317:588–593.PubMedCrossRefGoogle Scholar
  33. The University of Texas MD Anderson Cancer Center. Clinical practice algorithms. http://www.mdanderson.org/education-and-research/resources-for-professionals/clinical-tools-and-resources/practice-algorithms/index.html. Published August 22, 2012. Accessed November 19, 2012.
  34. van den Belt-Dusebout AW, Aleman BM, Besseling G, et al. Roles of radiation dose and chemotherapy in the etiology of stomach cancer as a second malignancy. Int J Radiat Oncol Biol Phys 2009;75:1420–1429.PubMedCrossRefGoogle Scholar
  35. van Leeuwen FE, Klokman WJ, Hagenbeek A, et al. Second cancer risk following Hodgkin’s disease: a 20-year follow-up study. J Clin Oncol 1994;12:312–325.PubMedGoogle Scholar
  36. Wethal T, Lund MB, Edvardsen T, et al. Valvular dysfunction and left ventricular changes in Hodgkin’s lymphoma survivors. A longitudinal study. Br J Cancer 2009;101:575–581.PubMedCrossRefPubMedCentralGoogle Scholar
  37. Yeh ET, Tong AT, Lenihan DJ, et al. Cardiovascular complications of cancer therapy: diagnosis, pathogenesis, and management. Circulation 2004;109:3122–3131.PubMedCrossRefGoogle Scholar

Copyright information

© The University of Texas M. D. Anderson Cancer Center 2015

Authors and Affiliations

  • Maria Alma Rodriguez
    • 1
  • Leslie Ballas
    • 2
  • Kristin Simar
    • 1
  1. 1.Department of Lymphoma and MyelomaThe University of Texas MD Anderson Cancer CenterHoustonUSA
  2. 2.Valley Radiotherapy AssociatesLos AngelesUSA

Personalised recommendations